Eli Lilly’s Retatrutide Outperforms Ozempic in Diabetes Trial
ISLAMABAD: (News Desk) - Eli Lilly said Wednesday that its experimental obesity drug, retatrutide, delivered greater weight loss and better blood sugar control than Novo Nordisk’s Ozempic in a late-stage clinical trial involving patients…